Valuation: Mymetics Corporation

Market Cap 439K 386K 355K 333K 623K 41.41M 635K 4.26M 1.65M 20.4M 1.65M 1.61M 70.96M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 63.42M 58.36M 54.67M 102M 6.81B 104M 701M 271M 3.35B 271M 265M 11.66B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 2012-11-18
Change 5-day change 1-year change 3-year change Capi.($)
-10.24%+8.79% - - 45
+4.43%+0.21%+60.07%+115.25% 52.88B
+1.58%+19.37%+75.37%+85.18% 50.98B
-0.23%-2.41%-14.36%-16.00% 22.81B
+0.98%+6.11%-1.35%+423.40% 22.43B
+2.03%+10.85%+30.31%-12.32% 17.01B
+0.88%+5.07%+28.91%-34.26% 15.91B
+0.68%+1.51%+16.43%+168.03% 13.29B
+3.02%+18.32%+141.11%+308.04% 13.58B
+0.79%+2.79%+80.29%+116.18% 11.75B
Average +0.39%+5.85%+46.31%+128.17% 24.52B
Weighted average by Cap. +1.99%+6.29%+48.56%+120.53%

Financials

2021 2022
Net sales 430K 378K 348K 326K 610K 40.59M 623K 4.18M 1.62M 19.99M 1.61M 1.58M 69.55M 1.03M 904K 832K 779K 1.46M 97.03M 1.49M 9.99M 3.87M 47.8M 3.86M 3.78M 166M
Net income -4.73M -4.16M -3.83M -3.59M -6.71M -446M -6.85M -45.95M -17.8M -220M -17.76M -17.37M -765M -4.8M -4.23M -3.89M -3.64M -6.82M -454M -6.96M -46.68M -18.09M -223M -18.04M -17.65M -777M
Net Debt 67.1M 59M 54.29M 50.86M 95.23M 6.33B 97.16M 652M 253M 3.12B 252M 246M 10.85B 71.68M 63.04M 58M 54.34M 102M 6.77B 104M 696M 270M 3.33B 269M 263M 11.59B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-